High-Intensity Focused Ultrasound (HIFU)

What is HIFU?

High-intensity focused ultrasound (HIFU) is a technique that uses heat to destroy the area of the prostate gland affected with cancer by means of a probe that gives out a beam of high-intensity focused ultrasound. 

Who is eligible for HIFU?

You may be eligible for HIFU treatment if:
1) You have a low-grade cancer (cancer which has not spread outside the prostate gland). 
2) You have recurrent prostate cancer after radiotherapy (known as salvage HIFU).
 
What are the advantages and disadvantages of HIFU treatment?

Deciding if HIFU treatment is right for you is a decision you should make after knowing the advantages and disadvantages and discussing them with your doctor. 
 
Advantages of HIFU Disadvantages of HIFU
Minimally invasive Scarring of the prostate
Minimal hospital stays Costly
Minimal side effects New treatment/not much data
  Appears to be less effective at controlling cancer
 
What are the possible complications of HIFU treatment?

As with any procedure, there are possible complications and side effects of HIFU treatment. Everyone responds differently to varying forms of treatment. Doctors have found that there is a slightly higher risk of some patients (3 to 4%) developing a fistula, which is an opening between the urinary system and the bowel. 

Is HIFU available in Canada?

HIFU is currently only offered in select centres in Canada, as it is still considered an experimental procedure. There is insufficient evidence to recommend HIFU as a routine treatment. 
 
HIFU is not covered by Canadian public health insurance – you will need to pay for the procedure yourself. 
 
Please visit the following sites to learn more about HIFU treatments in Canada.
 
 

For more information and support:





Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
RFP: Content Development and Delivery of an Accredited Electronic Continuing Medical Education Course for Prostate Cancer Specialists

Prostate Cancer Canada invites applications from service providers interested in the development, promotion and delivery of an accredited electronic Continuing Medical Education course targeting prostate cancer specialists, including urologists.
More

Prostate Cancer Canada announces new President and CEO

Toronto, December 21, 2017 – After five successful years under the leadership and guidance of outgoing President and CEO, Rocco Rossi, Prostate Cancer Canada (PCC) is excited to announce the appointment of a most worthy successor in Peter Coleridge, past national CEO of the Canadian Mental Health Association and current national President and CEO of Big Brothers Big Sisters of Canada.
More

Université de Sherbrooke Researchers’ Findings Published in Cancer Research

Sherbrooke, November 16, 2017 – Prostate cancer, the most common cancer in men, affects one out of seven Canadian men.
More


Click here for news archive